Three-phase scintigraphy as an addition to the traditional singlephoton diagnosis of patients with neuroendocrine tumors
https://doi.org/10.33667/2078-5631-2025-26-29-33
Abstract
Introduction. Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms originating from enterochromaphin cells of the diffuse endocrine system. Nuclear medicine, imaging of somatostatin receptors, plays a leading role in identifying and assessing the status of NET.
Purpose. To determine the complex of X-ray and radiological signs characteristic of neuroendocrine tumors and compare them with an immunohistochemical study of expression levels of somatostatin receptors.
Materials and methods. The study included 119 patients with NET of various localizations who were examined at the N. N. Blokhin National Research Medical Center of Oncology from 2019 to 2022. There are 75 women and 44 men among them (63 % and 37 %, respectively). The age of the patients ranged from 1 to 84 years (median – 60).
Results. When comparing the Grade values depending on the «flash» in a dynamic study, we found statistically significant differences (p=0.010).
Conclusions. Clinical and radiological criteria for the qualitative characteristics of dynamic scintigraphy in NET make it possible to predict the effectiveness of treatment and the course of the disease, and the use of 3-phase scintigraphy with 99mTc-tectrotide makes it possible to diagnose a neuroendocrine tumor in 46 % of patients before receiving histological material or when it is impossible to obtain it.
About the Authors
S. M. Kaspshik
N. N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation
Russian Federation
Kaspshik Stepan M., radiologist at Radioisotope Diagnostics branch No. 1 of Dept of Radioisotope Diagnostics and Therapy
Moscow
AuthorID: 976833
A. D. Ryzhkov
N. N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation
Russian Federation
Ryzhkov Alexey D., DM Sci, leading researcher at Radioisotope Diagnostics branch No. 1 of Dept of Radioisotope Diagnostics and Therap
Moscow
AuthorID: 424746
A. S. Krylov
N. N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation
Russian Federation
Krylov Aleksandr S., PhD Med, head of Radioisotope Diagnostics branch No. 1 of Dept of Radioisotope Diagnostics and Therapy
Moscow
E. V. Artamonova
N. N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation
Russian Federation
Artamonova Elena V., DM Sci, head of Dept of Medicinal Methods of Treatment (Chemotherapy) No. 1
Moscow
AuthorID: 707707
A. A. Markovich
N. N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation
Russian Federation
Markovich Alla A., PhD Med, senior researcher at outpatient department
Moscow
AuthorID: 898498
M. E. Bilik
N. N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation
Russian Federation
Bilik Maria E., radiologist at Radioisotope Diagnostics branch No. 1 of Dept of Radioisotope Diagnostics and Therapy
Moscow
AuthorID: 976615
References
1. Slashchuk K. Yu., Rumyantsev P. O., Degtyarev M. V., Serzhenko S. S., Baranova O. D., Trukhin A. A., Sirota Ya. I. Molecular Imaging of Neuroendocrine Tumors by Somatostatin- Receptor Scintigraphy (SPEСT/СT) with 99mTc-Tektrotyd Medical Radiology and Radiation Safety. 2020; 65 (2): 44–49. (In Russ.).
2. Sultana Q, Kar J, Verma A, Sanghvi S, Kaka N, Patel N, Sethi Y, Chopra H, Kamal MA, Greig NH. A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management. J Clin Med. 2023 Aug 5; 12 (15): 5138. DOI: 10.3390/jcm12155138. PMID: 37568540; PMCID: PMC 10420169
3. Dasari A., Shen C., Halperin D. M., Zhao B., Zhou S., Xu Y., Shih T., Yao J. C. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncol. 2017; 3: 1335–1342. DOI: 10.1001/jamaoncol.2017.0589
4. Williams E. The Classification of Carcinoid Tumours. Lancet. 1963; 281 (7275): 238–9. DOI: 10.1016/s0140-6736 (63) 90951‑6
5. Rindi G, Arnold R, Bosman FT. et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH. et al, editors. WHO classification of tumors of the digestive system. Lyon: IARC? 2010. P. S 13–S 14.
6. Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Welldifferentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016; 40 (9): 1192–202. DOI: 10.1097/PAS.0000000000000662
7. Briganti V, Cuccurullo V, and Berti V. et al. (2020) 99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases).2020; 13 (Issue 3):166–176. DOI: 10.2174/1874471013666191230143610
8. Mesquita CT, Palazzo IC, Rezende MF. Ga-DOTA PET/CT: the first-line functional imaging modality in the management of patients with neuroendocrine tumors. Radiol Bras. 2022 Mar-Apr; 55 (2): VII–VIII. DOI: 10.1590/0100-3984.2022.55.2e2
9. Kaspshik S. M., Artamonova E. V., Markovich A. A., Bilik M. E., Emelyanova G. S., Ryzhkov A. D. Myths about inexpediency of carrying out peptide receptor radionuclide diagnostics in patients with neuroendocrine tumors. Medical alphabet. 2021; 19: 18–22. (In Russ.). https://doi.org/10.33667/2078‑5631‑2021‑19‑18‑22
10. Alevroudis E, Spei ME, Chatziioannou SN, et al. Clinical utility of 18F-FDG PET in neuroendocrine tumors prior to peptide receptor radionuclide therapy: a systematic review and meta-analysis. Cancers (Basel). 2021; 13: 1813. DOI: 10.3390/cancers13081813
11. Kaspshik S. M., Dolgushin M. B., Artamonova E. V., Markovich A. A., Ryzhkov A. D., Emelyanova G. S., Bilik M. E. Clinical utility of scintigraphy and SPECT/CT with 99mTc-Tectrotyd in patients with neuroendocrine tumors. Medical alphabet. 2020 (20): 42–45. (In Russ.). https://doi.org/10.33667/2078‑5631‑2020‑20‑42‑45
12. Moura M. M., Cabrera R. A., Esteves S., Cavaco B. M., Soares P., Leite V. Correlation of Molecular Data with Histopathological and Clinical Features in a Series of 66 Patients with Medullary Thyroid Carcinoma. J. Endocrinol. Investig. 2021; 44: 1837–1846. DOI: 10.1007/s40618‑020‑01456‑6
13. Gallo M., Campione S., Di Vito V., Fortunati N., Lo Calzo F., Messina E., Ruggeri R. M., Faggiano A., Colao A. A. L. Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues. Front. Endocrinol. 2021; 11: 610230. DOI: 10.3389/fendo.2020.610230
Review
For citations:
Kaspshik S.M., Ryzhkov A.D., Krylov A.S., Artamonova E.V., Markovich A.A., Bilik M.E. Three-phase scintigraphy as an addition to the traditional singlephoton diagnosis of patients with neuroendocrine tumors. Medical alphabet. 2025;(26):29‑33. (In Russ.) https://doi.org/10.33667/2078-5631-2025-26-29-33
Views:
22
Email this article 